BR112019007737A2 - sais de piridínio quaternário do tipo azo com eficácia antibacteriana acentuada por ácido, métodos de uso, métodos de síntese e usos dos mesmos - Google Patents

sais de piridínio quaternário do tipo azo com eficácia antibacteriana acentuada por ácido, métodos de uso, métodos de síntese e usos dos mesmos

Info

Publication number
BR112019007737A2
BR112019007737A2 BR112019007737A BR112019007737A BR112019007737A2 BR 112019007737 A2 BR112019007737 A2 BR 112019007737A2 BR 112019007737 A BR112019007737 A BR 112019007737A BR 112019007737 A BR112019007737 A BR 112019007737A BR 112019007737 A2 BR112019007737 A2 BR 112019007737A2
Authority
BR
Brazil
Prior art keywords
azo
methods
spq
acid
quaternary pyridinium
Prior art date
Application number
BR112019007737A
Other languages
English (en)
Inventor
Sun Jirun
Original Assignee
Ada Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ada Found filed Critical Ada Found
Publication of BR112019007737A2 publication Critical patent/BR112019007737A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C07D213/20—Quaternary compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/06—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C08F220/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F226/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F226/06—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438—Electrodes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)

Abstract

um novo sal de piridínio quaternário do tipo azo (azo-spq) mostra atividade acentuada em condições ácidas (por exemplo, ph = 5); em condições neutras ou básicas, este novo azo-spq mostra um nível muito menor (2 a 50 vezes menor) de atividade antibacteriana. o uso de tal antibiótico que acentua o estímulo pode responder diretamente à proliferação de bactérias. ajuda a reduzir ou prevenir a formação de agentes antibacterianos potentes no meio oral. as propriedades antibacterianas de azo-spq são ativadas quando o ph ambiental se torna ácido; este ácido ph pode ser indicativo do acúmulo de streptococcus mutans ou do início de cárie dentária.
BR112019007737A 2016-10-16 2017-10-05 sais de piridínio quaternário do tipo azo com eficácia antibacteriana acentuada por ácido, métodos de uso, métodos de síntese e usos dos mesmos BR112019007737A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662408826P 2016-10-16 2016-10-16
US15/723,763 US10836726B2 (en) 2016-10-16 2017-10-03 AZO-quaternary pyridinium salts with acid-enhanced antibacterial efficacy, methods of use, methods of synthesis, and uses thereof
PCT/US2017/055283 WO2018071262A1 (en) 2016-10-16 2017-10-05 Azo-quaternary pyridinium salts with acid-enhanced antibacterial efficacy, methods of use, methods of syntheses, and uses thereof

Publications (1)

Publication Number Publication Date
BR112019007737A2 true BR112019007737A2 (pt) 2019-07-09

Family

ID=61902635

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007737A BR112019007737A2 (pt) 2016-10-16 2017-10-05 sais de piridínio quaternário do tipo azo com eficácia antibacteriana acentuada por ácido, métodos de uso, métodos de síntese e usos dos mesmos

Country Status (9)

Country Link
US (1) US10836726B2 (pt)
EP (1) EP3526193A4 (pt)
JP (1) JP6857723B2 (pt)
KR (1) KR20190071751A (pt)
CN (1) CN109923100A (pt)
AU (1) AU2017342835A1 (pt)
BR (1) BR112019007737A2 (pt)
CA (1) CA3039381A1 (pt)
WO (1) WO2018071262A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113045778B (zh) * 2021-03-19 2022-05-31 常州大学 一种双重响应自修复水凝胶的制备方法
CN113185702B (zh) * 2021-05-06 2023-03-24 潍坊学院 一种基于硅氧烷-金属卟啉的多孔有机聚合物及其制备方法和在农药检测中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997519A (en) * 1972-05-15 1976-12-14 Gaf Corporation Method of producing quaternary pyridinium compounds
SU910703A1 (ru) * 1979-03-13 1982-03-07 Центральный научно-исследовательский институт шерстяной промышленности Активные азокрасители с фунгицидными свойствами
WO2002033005A2 (en) * 2000-10-19 2002-04-25 Trans Photonics, L.L.C. Novel substituted-polyaryl chromophoric compounds
US7288639B2 (en) * 2004-12-15 2007-10-30 L'oreal S.A. Dyssymmetrical diazo compounds having at least one 4-pyridinium unit and a cationic or non-cationic linker, compositions comprising them, method of coloring, and device
FR3060995B1 (fr) * 2016-12-22 2019-05-31 L'oreal Procede de coloration des fibres keratiniques mettant en oeuvre au moins un colorant 2- ou 4-azopyridinium particulier et au moins un colorant fluorescent

Also Published As

Publication number Publication date
EP3526193A1 (en) 2019-08-21
JP2019537569A (ja) 2019-12-26
JP6857723B2 (ja) 2021-04-14
US10836726B2 (en) 2020-11-17
CA3039381A1 (en) 2018-04-19
WO2018071262A1 (en) 2018-04-19
US20180105495A1 (en) 2018-04-19
AU2017342835A1 (en) 2019-05-02
KR20190071751A (ko) 2019-06-24
CN109923100A (zh) 2019-06-21
EP3526193A4 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
BR112018073199A2 (pt) corantes diméricos ou poliméricos ultrabrilhantes
BR112018070164A2 (pt) corantes diméricos ou poliméricos ultrabrilhantes
BR112014013974A8 (pt) derivados de sulfonamida benzílicos como moduladores de rorc
EA201691921A1 (ru) Устойчивые композиции не связанного в комплекс йода и способы их применения
BR112018012408A2 (pt) ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica?
BR112012016749A2 (pt) "d-aminoácido para uso no tratamento de biofilmes"
MX2020010847A (es) Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
BR112015006573A2 (pt) derivados de 3-fenilisoxazolina com ação herbicida
BR112015026847A2 (pt) tiazóis e usos dos mesmos
BR112014027117A8 (pt) Derivados de pirazol aminopirimidina como moduladores de lrrk2, seus usos, e composição
BR112015013485A2 (pt) derivados de benzilsulfonamida como moduladores de rorc
BR112019007737A2 (pt) sais de piridínio quaternário do tipo azo com eficácia antibacteriana acentuada por ácido, métodos de uso, métodos de síntese e usos dos mesmos
BR112018004343A2 (pt) compostos 1,2-dihidro-3h-pirrolo [1,2-c] imidazol-3-ona antibacterianos substituídos
UA115965C2 (uk) Композиція і спосіб для поліпшення сумісності водорозчинних гербіцидних солей
BR112015023829A2 (pt) composto de amidina e seu uso
PE20191486A1 (es) COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER
ECSP17043754A (es) Sistemas de revestimiento de piso de sacrificio antimicrobiano
JP2015534725A5 (pt)
BR112017003231A2 (pt) compostos heterobicíclicos e seu uso para o tratamento da tuberculose
ZA202307728B (en) Durable biofouling protection
MX2019003052A (es) Composiciones para compuestos de agente terapeutico de molecula pequeña.
BR112013001746A2 (pt) composição biocida, e, método para controlar o crescimento de microrganismos em um sistema aquoso ou contendo água.
BR112014028060A2 (pt) controle em escala de sulfato nos sistemas aquosos de baixo ph
BRPI0814667A2 (pt) Utilização de pelo menos um derivado oxima do 3,5-seco-4-nor-colestano ou um dos seus sais de adição com os ácidos aceitáveis, ou de um dos seus ésteres ou um dos sais de adição dos referidos ésteres com os ácidos aceitáveis.
BR112013021901B8 (pt) composição biocida e método para controlar o crescimento de microorganismo em um sistema aquoso ou contendo água

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.